Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Prognosis and outcomes of lymphocyte-predominant Hodgkin's lymphoma

Nature Clinical Practice Oncology volume 5, pages 368–369 (2008)Cite this article

An Erratum to this article was published on 01 August 2008

boxed-textNogová L et al. (2008) Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26: 434–439

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wirth A et al. (2005) Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 104: 1221–1229

    Article  Google Scholar 

  2. Nogová L et al. (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16: 1683–1687

    Article  Google Scholar 

  3. Schulz H et al. (2008) Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111: 109–111

    Article  CAS  Google Scholar 

  4. Wedgwood AR et al. (2007) Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all international prognostic score (IPS) groups and in patients who have PET positive disease after 2–3 cycles of therapy [abstract]. Blood 110 (ASH Annual Meeting Abstracts): a215

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. G Suh is a Medical Oncology Fellow in the Division of Cancer Medicine, and A Younes is Professor of Medicine and Director of Clinical and Translational Research in the Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.,

    Grace Suh & Anas Younes

Authors
  1. Grace Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anas Younes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anas Younes.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suh, G., Younes, A. Prognosis and outcomes of lymphocyte-predominant Hodgkin's lymphoma. Nat Rev Clin Oncol 5, 368–369 (2008). https://doi.org/10.1038/ncponc1153

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1153

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing